Evidence map›Paper›PMID 36776889›Full record

ArticleFrontiers in immunology2023

Caspase-11 promotes high-fat diet-induced NAFLD by increasing glycolysis, OXPHOS, and pyroptosis in macrophages.

Charles Drummer, Fatma Saaoud, Nirag C Jhala, Ramon Cueto, Yu Sun, Keman Xu, Ying Shao, Yifan Lu, Huimin Shen, Ling Yang and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Animals : an open access journal from MDPI · 2026
    Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Molecular medicine reports · 2026
    Article
  13. Review
  14. [Mechanisms of pyroptosis in metabolic diseases].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  15. Review
  16. Article
  17. Article
  18. The Protective Effect of Melatonin on LPS-Induced Myocardial InjuryCombinatorial chemistry & high throughput screening · 2025
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Charles DrummerCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Fatma SaaoudCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Nirag C JhalaDepartment of Pathology and Laboratory Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Ramon CuetoMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Yu SunCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Keman XuCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Ying ShaoCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Yifan LuCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Huimin ShenMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Ling YangDepartment of Medical Genetics and Molecular Biochemistry, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Yan ZhouBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, United States.
Jun YuMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Sheng WuMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Nathaniel W SnyderMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Wenhui HuMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Jia 'Joe' ZhuoTulane Hypertension & Renal Center of Excellence, Tulane University School of Medicine, New Orleans, LA, United States.
Yinghui ZhongSchool of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, United States.
Xiaohua JiangMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Hong WangMetabolic Disease Research and Thrombosis Research Center, Departments of Cardiovascular Sciences, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Xiaofeng YangCenters of Cardiovascular Research, Temple University Lewis Katz School of Medicine, Philadelphia, PA, United States.
Temple University · USDrexel University · USFox Chase Cancer Center · USTulane University · US

Funding

Role of Intracrine Angiotensin II in Kidney CellsR01DK067299 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI Jia Long Zhuo · 2004 to 2026
$6.5M
Brain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradicationR01MH130193 · NIMH · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Wenhui Hu, Binhua Julie Ling · 2022 to 2026
$4.0M
CD4 T cell-targeted nanoparticle in vivo delivery of CRISPR/Cas9 genome editors for HIV cureR01AI145034 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI HU, WENHUI · 2019 to 2023
$3.8M
Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cureR01AI174301 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu, Qingsheng Li · 2023 to 2026
$3.5M
CD40 monocyte in chronic kidney diseaseR01DK113775 · NIDDK · TEMPLE UNIV OF THE COMMONWEALTH · PI WANG, HONG · 2017 to 2021
$3.3M
Long-term microglia-targeted endogenous retrovirus-like particle (ERVLP) delivery of Cas12f editor to cure HIVR01DA056876 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI Wenhui Hu · 2022 to 2026
$3.0M
Caspase-1 activation mediates chronic kidney disease-accelerated atherosclerosisR01HL131460 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI CHOI, ERIC T., WANG, HONG · 2016 to 2019
$2.8M
The roles of miR-155 in regulating atherosclerosis and metabolically healthy obesityR01HL138749 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.6M
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activationR01HL147565 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2019 to 2022
$2.6M
LysoPI/GPR55 pathway promotes endothelial activation, vascular inflammation and atherosclerosisR01HL163570 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI Xiaofeng Yang · 2023 to 2026
$2.6M
Role of Proximal Tubule NHE3 in Angiotensin II-induced HypertensionR01DK102429 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI ZHUO, JIA LONG · 2014 to 2021
$2.5M
IL-35 suppression of endothelial cell activation and atherosclerosisR01HL132399 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2017 to 2020
$2.3M
NHLBI NIH HHS R01 HL131460NHLBI NIH HHS R01 HL132399NHLBI NIH HHS R01 HL138749NHLBI NIH HHS R01 HL147565NHLBI NIH HHS R01 HL153599NHLBI NIH HHS R01 HL163570NIAID NIH HHS R01 AI145034NIAID NIH HHS R01 AI174301NIDA NIH HHS R01 DA056876NIDDK NIH HHS R01 DK067299NIDDK NIH HHS R01 DK102429NIDDK NIH HHS R01 DK104116NIDDK NIH HHS R01 DK113775NIDDK NIH HHS R01 DK123144NIMH NIH HHS R01 MH130193
6 · The paper itself

Abstract

Introduction: Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% of the population and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD ranges from simple steatosis (non-alcoholic fatty liver) to non-alcoholic steatohepatitis (NASH). Hepatic macrophages, specifically Kupffer cells (KCs) and monocyte-derived macrophages, act as key players in the progression of NAFLD. Caspases are a family of endoproteases that provide critical connections to cell regulatory networks that sense disease risk factors, control inflammation, and mediate inflammatory cell death (pyroptosis). Caspase-11 can cleave gasdermin D (GSDMD) to induce pyroptosis and specifically defends against bacterial pathogens that invade the cytosol. However, it's still unknown whether high fat diet (HFD)-facilitated gut microbiota-generated cytoplasmic lipopolysaccharides (LPS) activate caspase-11 and promote NAFLD. Methods: To examine this hypothesis, we performed liver pathological analysis, RNA-seq, FACS, Western blots, Seahorse mitochondrial stress analyses of macrophages and bone marrow transplantation on HFD-induced NAFLD in WT and Casp11-/- mice. Results and Discussion: Our results showed that 1) HFD increases body wight, liver wight, plasma cholesterol levels, liver fat deposition, and NAFLD activity score (NAS score) in wild-type (WT) mice; 2) HFD increases the expression of caspase-11, GSDMD, interleukin-1β, and guanylate-binding proteins in WT mice; 3) Caspase-11 deficiency decreases fat liver deposition and NAS score; 4) Caspase-11 deficiency decreases bone marrow monocyte-derived macrophage (MDM) pyroptosis (inflammatory cell death) and inflammatory monocyte (IM) surface GSDMD expression; 5) Caspase-11 deficiency re-programs liver transcriptomes and reduces HFD-induced NAFLD; 6) Caspase-11 deficiency decreases extracellular acidification rates (glycolysis) and oxidative phosphorylation (OXPHOS) in inflammatory fatty acid palmitic acid-stimulated macrophages, indicating that caspase-11 significantly contributes to maintain dual fuel bioenergetics-glycolysis and OXPHOS for promoting pyroptosis in macrophages. These results provide novel insights on the roles of the caspase-11-GSDMD pathway in promoting hepatic macrophage inflammation and pyroptosis and novel targets for future therapeutic interventions involving the transition of NAFLD to NASH, hyperlipidemia, type II diabetes, metabolic syndrome, metabolically healthy obesity, atherosclerotic cardiovascular diseases, autoimmune diseases, liver transplantation, and hepatic cancers.

Indexed as

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseAnimalsCaspasesDiet, High-FatGlycolysisInflammationMacrophagesMiceOxidative PhosphorylationPyroptosisCaspasescaspase-11inflammationnon-alcoholic fatty liver disease (NAFLD)non-alcoholic steatohepatitis (NASH)pyroptosis

Identifiers

PMID36776889
PMCPMC9909353
OpenAlexW4318065636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.